Pralsetinib vs Selpercatinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: RET · full Non-Small Cell Lung Cancer pipeline

Pralsetinib

Marketed by Rigel Pharmaceuticals and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04222972 · Phase 3 · terminated

This was a randomized, active-controlled trial in 223 patients that met its primary progression-free-survival endpoint with a clear statistical result, but it was conducted open-label (patients and investigators knew which treatment was given), which limits confidence in an investigator-assessed endpoint like progression.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5) (met)

Result source: NCT04222972

Selpercatinib · Retevmo

Marketed by Eli Lilly and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT04194944 · Phase 3 · active, not recruiting

LIBRETTO-431 randomised 261 patients with RET fusion-positive NSCLC to selpercatinib or platinum-pemetrexed chemotherapy with or without pembrolizumab. Treatment was open-label, but progression was assessed by blinded independent central review. The primary endpoint, progression-free survival, was met (HR 0.465, 95% CI 0.309 to 0.699, p=0.0002 against chemotherapy plus pembrolizumab); the open-label design keeps the grade at moderate.

Next expected readout: December 2026 · NCT04268550 (registry estimate)

Reported efficacy

Event-Free Survival (EFS) (Randomization to disease recurrence/progression or death from any cause (estimated as up to 7 years)): Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026) (met)

Result source: NCT04819100

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointPralsetinibSelpercatinib
PFS, median18.7 vs 9vs SOCn 110NCT04222972
6 other results
24.8 vs 11.2vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
OS, median39.7bn 141NCT03037385
4 other results
33.0n 159NCT04194944
ORR65.5% vs 41.6%vs SOCn 110NCT04222972
18 other results
83.7% vs 65.1%vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
  • 83.6% vs 62.7% n 159 · Phase 3 · secondary NCT04194944
Duration of response, median20.6 vs 9.7vs SOCn 72NCT04222972
7 other results
24.2 vs 11.5vs Pemetrexed and Platinum With Pembrolizumabn 108NCT04194944
1 other result

PFS, median

Pralsetinib
18.7 vs 9vs SOCn 110NCT04222972
6 other results
Selpercatinib
24.8 vs 11.2vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result

OS, median

Pralsetinib
39.7bn 141NCT03037385
4 other results
Selpercatinib
33.0n 159NCT04194944

ORR

Pralsetinib
65.5% vs 41.6%vs SOCn 110NCT04222972
18 other results
Selpercatinib
83.7% vs 65.1%vs Pemetrexed and Platinum With Pembrolizumabn 129NCT04194944
1 other result
  • 83.6% vs 62.7% n 159 · Phase 3 · secondary NCT04194944

Duration of response, median

Pralsetinib
20.6 vs 9.7vs SOCn 72NCT04222972
7 other results
Selpercatinib
24.2 vs 11.5vs Pemetrexed and Platinum With Pembrolizumabn 108NCT04194944
1 other result
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Pralsetinib: 4 of 5 rows · Selpercatinib: 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPralsetinibSelpercatinib
Disease Control
responder rate · % of participants
88.2% (n=110) vs 79.6% (n=113) SOCa,b
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
89.1% (n=129) vs 84.3% (n=83) Pemetrexed and Platinum With Pembrolizumabc,a,b
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more dose
89.3% (n=159) vs 82.4% (n=102) Pemetrexed and Platinum With or Without Pembrolizumab
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Dropout rate
n/a: no completion milestoned
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
n/a: no completion milestone400 mg
NCT03037385 · Phase 1/2
—400 mg QD
NCT03037385 · Phase 1/2
n/a: no completion milestone600 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone300 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone200 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone200/100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone100/100 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone60 mg
NCT03037385 · Phase 1/2
n/a: no completion milestone30 mg
NCT03037385 · Phase 1/2
61.6%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Discontinued due to AEs
0.9%d
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
0%400 mg
NCT03037385 · Phase 1/2
—400 mg QD
NCT03037385 · Phase 1/2
0%600 mg
NCT03037385 · Phase 1/2
0%300 mg
NCT03037385 · Phase 1/2
0%200 mg
NCT03037385 · Phase 1/2
0%200/100 mg
NCT03037385 · Phase 1/2
20%100 mg
NCT03037385 · Phase 1/2
0%100/100 mg
NCT03037385 · Phase 1/2
0%60 mg
NCT03037385 · Phase 1/2
0%30 mg
NCT03037385 · Phase 1/2
—
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Serious AEs
62%d
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 10 more results
—400 mg
NCT03037385 · Phase 1/2
70.6%400 mg QD
NCT03037385 · Phase 1/2
—600 mg
NCT03037385 · Phase 1/2
—300 mg
NCT03037385 · Phase 1/2
—200 mg
NCT03037385 · Phase 1/2
—200/100 mg
NCT03037385 · Phase 1/2
—100 mg
NCT03037385 · Phase 1/2
—100/100 mg
NCT03037385 · Phase 1/2
—60 mg
NCT03037385 · Phase 1/2
—30 mg
NCT03037385 · Phase 1/2
34.8%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Most frequent reported AEs
d
anaemia 48.1%
constipation 43.5%
aspartate aminotransferase increased 41.7%
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
400 mg QD
anaemia 52.8%
aspartate aminotransferase increased 50.6%
constipation 44.1%
NCT03037385 · Phase 1/2
aspartate aminotransferase increased 61.4%
alanine aminotransferase increased 60.1%
hypertension 48.1%
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

Notes

  1. aTreatment context has not been resolved for both arms.
  2. bThe assessment timepoint is not available for both results.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for 10 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Pralsetinib

Clinical Benefit 74.5% (n=110) vs 58.4% (n=113) SOC
responder rate · % of participants
NCT04222972 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
ORR 41.7% (n=12)400 mg
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 17 more results
25% (n=4)600 mg
NCT03037385 · Phase 1/2
45.5% (n=11)300 mg
NCT03037385 · Phase 1/2
38.5% (n=13)200 mg
NCT03037385 · Phase 1/2
75% (n=4)200/100 mg
NCT03037385 · Phase 1/2
40% (n=5)100 mg
NCT03037385 · Phase 1/2
80% (n=5)100/100 mg
NCT03037385 · Phase 1/2
50% (n=6)60 mg
NCT03037385 · Phase 1/2
0% (n=2)30 mg
NCT03037385 · Phase 1/2
63.1% (n=130)
NCT03037385 · Phase 1/2
73.9% (n=23)
NCT03037385 · Phase 1/2
78.3% (n=106)
NCT03037385 · Phase 1/2
56.7% (n=60)
NCT03037385 · Phase 1/2
77.8% (n=72)
NCT03037385 · Phase 1/2
85.2% (n=27)
NCT03037385 · Phase 1/2
46.4% (n=28)
NCT03037385 · Phase 1/2
19% (n=21)
NCT03037385 · Phase 1/2
7.7% (n=13)
NCT03037385 · Phase 1/2
Duration of Response 31.8 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
22.6 months
NCT03037385 · Phase 1/2
13.4 months
NCT03037385 · Phase 1/2
21.7 months
NCT03037385 · Phase 1/2
51.8 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
11.1 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
5.5 months
NCT03037385 · Phase 1/2
Clinical Benefit 74.6% (n=130)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
78.3% (n=23)
NCT03037385 · Phase 1/2
80.2% (n=106)
NCT03037385 · Phase 1/2
80% (n=60)
NCT03037385 · Phase 1/2
90.3% (n=72)
NCT03037385 · Phase 1/2
85.2% (n=27)
NCT03037385 · Phase 1/2
60.7% (n=28)
NCT03037385 · Phase 1/2
28.6% (n=21)
NCT03037385 · Phase 1/2
23.1% (n=13)
NCT03037385 · Phase 1/2
Disease Control 91.5% (n=130)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 8 more results
91.3% (n=23)
NCT03037385 · Phase 1/2
89.6% (n=106)
NCT03037385 · Phase 1/2
95% (n=60)
NCT03037385 · Phase 1/2
93.1% (n=72)
NCT03037385 · Phase 1/2
96.3% (n=27)
NCT03037385 · Phase 1/2
75% (n=28)
NCT03037385 · Phase 1/2
42.9% (n=21)
NCT03037385 · Phase 1/2
69.2% (n=13)
NCT03037385 · Phase 1/2
PFS 16.4 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 6 more results
13 months
NCT03037385 · Phase 1/2
12.1 months
NCT03037385 · Phase 1/2
24.9 months
NCT03037385 · Phase 1/2
55.3 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
7 months
NCT03037385 · Phase 1/2
Overall Survival 39.7 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 6 more results
46 months
NCT03037385 · Phase 1/2
50.1 months
NCT03037385 · Phase 1/2
42.2 months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
NA months
NCT03037385 · Phase 1/2
10.3 months
NCT03037385 · Phase 1/2
Intracranial ORR 53.8% (n=13)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 2 more results
100% (n=1)
NCT03037385 · Phase 1/2
0% (n=1)
NCT03037385 · Phase 1/2
Intracranial Clinical Benefit 61.5% (n=13)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 2 more results
100% (n=1)
NCT03037385 · Phase 1/2
0% (n=1)
NCT03037385 · Phase 1/2
Intracranial Disease Control 76.9% (n=13)
responder rate · % of participants
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 2 more results
100% (n=1)
NCT03037385 · Phase 1/2
0% (n=1)
NCT03037385 · Phase 1/2
Intracranial Duration of Response 28.3 months
time to event · months
No placebo or comparator arm
NCT03037385 · Phase 1/2
show 1 more result
11.3 months
NCT03037385 · Phase 1/2

Selpercatinib

PFS2 NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs NA Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Intracranial ORR 81% (n=21) vs 57.1% (n=21) Pemetrexed and Platinum With Pembrolizumab
responder rate · % of participants
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
84% (n=25) vs 50% (n=26) Pemetrexed and Platinum With or Without Pembrolizumab
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Intracranial Duration of Response NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 13.4 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Pulmonary Symptoms NA vs 1.9 Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs 1.6 Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Time to CNS Progression NA vs NA Pemetrexed and Platinum With Pembrolizumab months
time to event · months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
show 1 more result
NA vs NA Pemetrexed and Platinum With or Without Pembrolizumab months
NCT04194944 · Phase 3 · Non-Small Cell Lung Cancer · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pralsetinib's landscape · Selpercatinib's landscape